The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer (Q37929371)

25 August 2017

1 reference

title

The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer (English)

1 reference

25 August 2017

R Wendel Naumann

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

7 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

123

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

411-420

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

7 January 2021

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Targeting the phosphoinositide 3-kinase pathway in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

The PI3K pathway as drug target in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

The phosphoinositide 3-kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Status of PI3K inhibition and biomarker development in cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Ras, PI(3)K and mTOR signalling controls tumour cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

PI3K pathway alterations in cancer: variations on a theme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Dissecting the role of mTOR: lessons from mTOR inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Obesity and cancer risk: the role of the insulin-IGF axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Molecular and pathologic aspects of endometrial carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

High frequency of mutations of the PIK3CA gene in human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Genetics of endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Should individual PI3 kinase isoforms be targeted in cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Resistance to chemotherapy and hormone therapy in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

PTEN augments doxorubicin-induced apoptosis in PTEN-null Ishikawa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Synergistic effect of rapamycin and cisplatin in endometrial cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Akt/GSK3 signaling in the action of psychotropic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.002

10.1016/J.YGYNO.2011.08.002

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference